title: [Mepartricin in BPH. A new dosage approach].
abstract: The authors assessed the validity of a treatment with mepartricin in BPH at the dose of 150,000 U in a once-a-day evening administration for 6 months. The results from the controlled study were compared with those obtained in a homogeneous group of patients treated with placebo. The analysis of the data obtained would suggest a preferential opinion in favour of the group treated with mepartricin which was effective in improving the symptomatology. Some hypothesis are put forward to interpret the results.
authors.affiliation: II Facoltà di Medicina e Cbirurgia, Università degli Studi, Napoli.
authors.forename: D
authors.initials: D
authors.lastname: Prezioso
authors.forename: F
authors.initials: F
authors.lastname: Fabrizio
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: T
authors.initials: T
authors.lastname: Lotti
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008613:Mepartricin / Q000627:therapeutic use*; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D008613:Mepartricin